Trial Profile
Multicenter, placebo-controlled, double-blind, randomized controlled trial of daikenchuto for patients with functional constipation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2021
Price :
$35
*
At a glance
- Drugs TU 100 (Primary)
- Indications Constipation
- Focus Therapeutic Use
- 23 May 2021 Primary endpoint (To evaluate the efficacy of daikenchuto for 4 weeks on symptoms, colonic transit time and gas volume in Japanese patients with chronic constipation) has been met as per results presented at the Digestive Disease Week 2021.
- 23 May 2021 Results assessing efficacy and safety of DKT for treating chronic constipation, presented at the Digestive Disease Week 2021.
- 16 Oct 2018 Status changed from recruiting to active, no longer recruiting.